Proteins and Molecular Pathways Relevant for the Malignant Properties of Tumor-Initiating Pancreatic Cancer Cells.
Animals
Cell Line, Tumor
Gene Expression Regulation, Neoplastic
Humans
Mice, Nude
Neoplasm Proteins
/ genetics
Neoplastic Stem Cells
/ metabolism
Pancreatic Neoplasms
/ genetics
Principal Component Analysis
Proteome
/ metabolism
Proteomics
RNA, Messenger
/ genetics
Reproducibility of Results
Signal Transduction
Xenograft Model Antitumor Assays
CSCs
LGALS3BP
MAC-2-BP
MRP14
MRP8
S100 proteins
S100A8
S100A9
TICs
cancer stem cells
differential proteome analysis
functional assays
proteomics
tumor grafting model
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
03 06 2020
03 06 2020
Historique:
received:
30
04
2020
revised:
26
05
2020
accepted:
30
05
2020
entrez:
7
6
2020
pubmed:
7
6
2020
medline:
6
3
2021
Statut:
epublish
Résumé
Cancer stem cells (CSCs), a small subset of the tumor bulk with highly malignant properties, are deemed responsible for tumor initiation, growth, metastasis, and relapse. In order to reveal molecular markers and determinants of their tumor-initiating properties, we enriched rare stem-like pancreatic tumor-initiating cells (TICs) by harnessing their clonogenic growth capacity in three-dimensional multicellular spheroid cultures. We compared pancreatic TICs isolated from three-dimensional tumor spheroid cultures with nontumor-initiating cells (non-TICs) enriched in planar cultures. Employing differential proteomics (PTX), we identified more than 400 proteins with significantly different expression in pancreatic TICs and the non-TIC population. By combining the unbiased PTX with mRNA expression analysis and literature-based predictions of pro-malignant functions, we nominated the two calcium-binding proteins S100A8 (MRP8) and S100A9 (MRP14) as well as galactin-3-binding protein LGALS3BP (MAC-2-BP) as putative determinants of pancreatic TICs. In silico pathway analysis followed by candidate-based RNA interference mediated loss-of-function analysis revealed a critical role of S100A8, S100A9, and LGALS3BP as molecular determinants of TIC proliferation, migration, and in vivo tumor growth. Our study highlights the power of combining unbiased proteomics with focused gene expression and functional analyses for the identification of novel key regulators of TICs, an approach that warrants further application to identify proteins and pathways amenable to drug targeting.
Identifiants
pubmed: 32503348
pii: cells9061397
doi: 10.3390/cells9061397
pmc: PMC7349116
pii:
doi:
Substances chimiques
Neoplasm Proteins
0
Proteome
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
J Biol Chem. 1998 May 15;273(20):12427-35
pubmed: 9575199
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Mol Cell Proteomics. 2005 Apr;4(4):523-33
pubmed: 15684406
Bioinformatics. 2007 Jan 15;23(2):e191-7
pubmed: 17237091
J Proteome Res. 2009 Oct;8(10):4604-14
pubmed: 19673542
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
Int J Oncol. 2020 Feb;56(2):581-595
pubmed: 31894262
EMBO Mol Med. 2012 Mar;4(3):218-33
pubmed: 22294553
Nat Rev Cancer. 2015 Feb;15(2):96-109
pubmed: 25614008
Mol Cell Biol. 2003 Apr;23(7):2564-76
pubmed: 12640137
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nucleic Acids Res. 2016 Dec 15;44(22):11033
pubmed: 27683222
Biochem Biophys Res Commun. 2017 Nov 4;493(1):592-597
pubmed: 28867179
Stem Cells Transl Med. 2019 Jan;8(1):75-81
pubmed: 30328686
Biophys Rev. 2018 Dec;10(6):1617-1629
pubmed: 30382555
Mol Cancer Res. 2008 Oct;6(10):1544-53
pubmed: 18922970
Nat Cell Biol. 2006 Dec;8(12):1321-3
pubmed: 17139281
J Proteomics. 2017 Jan 6;150:310-322
pubmed: 27746256
Gastroenterology. 2011 Dec;141(6):2218-2227.e5
pubmed: 21864475
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Cell Physiol Biochem. 2018;47(5):2109-2125
pubmed: 29975934
Clin Cancer Res. 2012 Aug 15;18(16):4277-84
pubmed: 22896694
Cancer Res. 2012 May 1;72(9):2228-38
pubmed: 22389450
PLoS One. 2011;6(6):e20636
pubmed: 21695188
J Proteomics. 2016 Mar 16;136:1-12
pubmed: 26850699
Eur J Pharmacol. 2009 Dec 25;625(1-3):73-83
pubmed: 19835859
J Natl Cancer Inst. 2010 Mar 3;102(5):340-51
pubmed: 20164446
Anal Chem. 2008 Jun 15;80(12):4696-710
pubmed: 18479145
Methods Mol Biol. 2007;397:67-78
pubmed: 18025714
Mol Cell Biol. 2003 Feb;23(3):1034-43
pubmed: 12529407
Nat Med. 2011 Mar;17(3):313-9
pubmed: 21386835
J Proteome Res. 2010 Jul 2;9(7):3394-402
pubmed: 20486718
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
Annu Rev Pathol. 2016 May 23;11:47-76
pubmed: 27193450
Nat Methods. 2016 Aug 30;13(9):741-8
pubmed: 27575624
PLoS Med. 2008 Jun 10;5(6):e123
pubmed: 18547137
Eur J Cancer. 2006 Mar;42(4):437-45
pubmed: 16406505
Methods Mol Biol. 2018;1711:133-148
pubmed: 29344888
Nature. 2014 May 1;509(7498):49-54
pubmed: 24670665
Br J Cancer. 2014 Jul 29;111(3):486-96
pubmed: 25003666
Semin Cancer Biol. 2015 Apr;31:16-27
pubmed: 24956577
Neoplasia. 1999 Apr;1(1):50-62
pubmed: 10935470
Br J Cancer. 2019 Jul;121(1):65-75
pubmed: 31123345
Anal Chem. 2000 Sep 15;72(18):4386-93
pubmed: 11008774
Cancer Res. 2009 Feb 15;69(4):1284-92
pubmed: 19190345
Semin Cancer Biol. 2019 Aug;57:19-26
pubmed: 30273655
J Immunol. 2003 Sep 1;171(5):2602-9
pubmed: 12928412
Gut. 2013 Feb;62(2):317-26
pubmed: 23112132
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Electrophoresis. 2006 Jun;27(11):2126-38
pubmed: 16637017
Cancer. 2002 Jan 1;94(1):228-39
pubmed: 11815981
Mol Cell Proteomics. 2010 Nov;9(11):2529-44
pubmed: 20739354
Cancer Res. 2018 Jan 15;78(2):313-319
pubmed: 29311159
Gastroenterology. 2012 Jul;143(1):234-45.e7
pubmed: 22510202
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640192
Br J Cancer. 2016 Jun 14;114(12):1305-12
pubmed: 27219018
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Anticancer Res. 2013 May;33(5):1785-91
pubmed: 23645722
Nature. 2012 Aug 23;488(7412):527-30
pubmed: 22854777
J Proteome Res. 2013 Jun 7;12(6):2791-804
pubmed: 23679566
Stem Cells. 2008 Dec;26(12):3037-46
pubmed: 18802034
J Mol Med (Berl). 2013 Jan;91(1):83-94
pubmed: 22864925
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Cancer Sci. 2017 Mar;108(3):283-289
pubmed: 28064442
Mol Cell Proteomics. 2011 Dec;10(12):M111.011635
pubmed: 21955398
PLoS Genet. 2007 Sep;3(9):1724-35
pubmed: 17907809
World J Gastroenterol. 2016 Jul 14;22(26):5971-6007
pubmed: 27468191
Gastroenterology. 2013 Jun;144(6):1241-8
pubmed: 23622133
Semin Cancer Biol. 2018 Apr;49:37-43
pubmed: 28811077
Cancers (Basel). 2018 Jan 26;10(2):
pubmed: 29373514
Biochim Biophys Acta. 2015 Dec;1852(12):2706-11
pubmed: 26435083
J Innate Immun. 2012;4(1):31-40
pubmed: 21912088
Nat Cell Biol. 2013 Feb;15(2):126-34
pubmed: 23334500
Nat Cell Biol. 2006 Dec;8(12):1369-75
pubmed: 17128264
Carcinogenesis. 2010 Sep;31(9):1541-51
pubmed: 20622003
Cancer Res. 2007 Feb 1;67(3):1030-7
pubmed: 17283135
Mol Cancer. 2017 Feb 1;16(1):29
pubmed: 28148257
Oncotarget. 2017 Feb 28;8(9):14806-14820
pubmed: 28122356
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102
Int J Oncol. 2016 Jul;49(1):265-75
pubmed: 27176937
Cell Stem Cell. 2011 Nov 4;9(5):433-46
pubmed: 22056140